Adma Biologics Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.32%.
Did ADMA Beat Earnings? Q4 2025 Results
ADMA Biologics closed out 2025 on strong footing, reporting fourth-quarter revenue of $139.16 million, an 18% year-over-year increase, with earnings per share of $0.20 meeting analyst expectations. The primary engine behind the quarter was ASCENIV, the company's high-margin immunoglobulin therapy, which drove full-year revenue of $510.17 million, up 20% from the prior year, while contributing to gross margin expansion that reached 63.8% in Q4 versus 53.9% a year earlier. That margin improvement reflects the successful integration of yield-enhanced production processes, with 2026 expected to represent the first full year of that output running through commercial operations. Adjusted EBITDA surged 52% in the quarter to $73.59 million, underscoring the operating leverage building in the business. Looking ahead, management reiterated guidance for revenue exceeding $635.00 million in 2026 and a path toward $1.10 billion by 2029, confidence the company reinforced by launching a $200.00 million share repurchase initiative, including a $125.00 million accelerated agreement with JPMorgan.
- Record ASCENIV demand with 51% year-over-year revenue growth driven by strong prescriber adoption and broad payer access
- Yield-enhanced production fully integrated into commercial operations driving gross margin expansion to 57.4% for FY 2025 from 51.5% in FY 2024
- Q4 2025 gross margins reached 63.8%, up from 53.9% in Q4 2024
- Continued mix shift toward higher-margin IVIG products, particularly ASCENIV
- Real-world data publications reinforcing ASCENIV differentiation and adoption
“2025 marked a year of disciplined execution, record performance and meaningful strategic progress for ADMA, and we are entering 2026 with significant momentum. Record ASCENIV demand, strong prescriber adoption and broad payer access underscores the strength and durability of our commercial platform and the continued expansion of the IVIG end market. With ASCENIV still forecasted to be early in its penetration curve and driven by our vertically integrated manufacturing model and enhanced plasma supply visibility, we believe ADMA is well positioned to deliver outsized revenue growth, higher margins and increasing earnings power in the years ahead.”
ADMA Biologics CEO, on the earnings call
Forward Guidance & Outlook
ADMA reiterated its previously provided multi-year financial guidance. For FY 2026, total revenue is expected to exceed $635 million, Adjusted Net Income to exceed $255 million, and Adjusted EBITDA to exceed $360 million. For FY 2027, total revenue is expected to exceed $775 million, Adjusted Net Income to exceed $315 million, and Adjusted EBITDA to exceed $455 million. By fiscal year 2029, the company targets greater than $1.1 billion in total annual revenue and at least $700 million in Adjusted EBITDA, representing approximately 20% and 30% compound annual growth rates, respectively. The company expects continued gross margin improvement in FY 2026, reflecting the first full year of yield-enhanced production and continued mix shift toward higher-margin IVIG products. ADMA expects strong cash generation, strategy-driven cost savings, and improved financial flexibility in 2026. The company anticipates a pre-IND meeting with the FDA for SG-001 in 2026, potentially enabling direct progression into a registrational trial.
ADMA YoY Financials
ADMA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.